EU Clinical Trials Register Glossary | Search for Clinical Trials
... If previous trials have indicated a treatment is safe and that it also shows promise in being able to treat a condition, phase III clinical trials begin. These involve large numbers of participants usually from several hundred to several thousand subjects, and are often spread between different hosp ...
... If previous trials have indicated a treatment is safe and that it also shows promise in being able to treat a condition, phase III clinical trials begin. These involve large numbers of participants usually from several hundred to several thousand subjects, and are often spread between different hosp ...
Vobilon Capsules. Capsule contains dry standardized extract of ginkgo biloba leaves... Vobilon is a herbal drug, contains gingko biloba extract, improving...
... From digestive system: dyspeptic disturbances, nausea. From central nervous system: headache, dizziness. DOSAGE AND ADMINISTRATION: Vobilon is administered orally during or after meal. Capsules should be swallowed ...
... From digestive system: dyspeptic disturbances, nausea. From central nervous system: headache, dizziness. DOSAGE AND ADMINISTRATION: Vobilon is administered orally during or after meal. Capsules should be swallowed ...
NIDA Prescription Drugs of Abuse
... addictive and dangerous when abused. This chart provides a brief look at some prescribed medications that—when used in ways or by people other than prescribed—have the potential for adverse medical consequences, including addiction. In 2010, approximately 16 million Americans reported using a prescr ...
... addictive and dangerous when abused. This chart provides a brief look at some prescribed medications that—when used in ways or by people other than prescribed—have the potential for adverse medical consequences, including addiction. In 2010, approximately 16 million Americans reported using a prescr ...
Revance Therapeutics, Inc.
... efficacy of botulinum toxin products. This predefined endpoint is not supported by the current best clinical science. While botulinum toxins may be paralytic agents, it is recognized by clinical scientific experts in this specialty that full paralysis at maximum contraction is not the most appropria ...
... efficacy of botulinum toxin products. This predefined endpoint is not supported by the current best clinical science. While botulinum toxins may be paralytic agents, it is recognized by clinical scientific experts in this specialty that full paralysis at maximum contraction is not the most appropria ...
generic prescribing - when not to do it!
... Generic Prescribing: When not to do to do it! Generic prescribing is generally more cost-effective than prescribing by brand name. There are some circumstances however in which it is preferable to prescribe by brand name. Some common examples are given below but note that this list is not exhaustive ...
... Generic Prescribing: When not to do to do it! Generic prescribing is generally more cost-effective than prescribing by brand name. There are some circumstances however in which it is preferable to prescribe by brand name. Some common examples are given below but note that this list is not exhaustive ...
cal...Clobenzorex (Asenlix®, Dinintel®, Finedal®)
... Clobenzorex is a relatively new anorectic drug that has been cited in the literature the last couple of years. It is not available in the United States, but is available in other countries such as Mexico, Spain, Argentina, and France. Clobenzorex is manufactured by Hoechst Marion Roussel as a 30 mg ...
... Clobenzorex is a relatively new anorectic drug that has been cited in the literature the last couple of years. It is not available in the United States, but is available in other countries such as Mexico, Spain, Argentina, and France. Clobenzorex is manufactured by Hoechst Marion Roussel as a 30 mg ...
Profile of Amisulpride
... known to prolong the QT interval, such as thioridazine and droperidol. Caution is advised when used with other renally cleared drugs eg. lithium, which may interfere with clearance of amisulpride. However, a study of the concomitant use of lithium carbonate (500mg twice daily) with low dose amisulpr ...
... known to prolong the QT interval, such as thioridazine and droperidol. Caution is advised when used with other renally cleared drugs eg. lithium, which may interfere with clearance of amisulpride. However, a study of the concomitant use of lithium carbonate (500mg twice daily) with low dose amisulpr ...
This is the seventh of the monthly Drug and Alcohol Supplements
... consider coming off their drugs or even resistant to the idea. This poses a problem for the GP. Explanation of the drug’s effects and limitations and encouragement of the patient’s ability to cope without them will often be sufficient to enable the patient to give it a try. Extra resources may be us ...
... consider coming off their drugs or even resistant to the idea. This poses a problem for the GP. Explanation of the drug’s effects and limitations and encouragement of the patient’s ability to cope without them will often be sufficient to enable the patient to give it a try. Extra resources may be us ...
Drug Discovery 3
... group of pharmaceutical chemists working at Pfizer's Sandwich, Kent research facility in England. It was initially studied for use in hypertension (high blood pressure) and angina pectoris (a form of ischaemic cardiovascular disease). Phase I clinical trials under the direction of Ian Osterloh sugge ...
... group of pharmaceutical chemists working at Pfizer's Sandwich, Kent research facility in England. It was initially studied for use in hypertension (high blood pressure) and angina pectoris (a form of ischaemic cardiovascular disease). Phase I clinical trials under the direction of Ian Osterloh sugge ...
Pfizer to Acquire Biorexis to Access Novel Technology Platform and
... therapeutic agents with substantially longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability as compared to other evolving protein therapeutic technologies. This new platform sup ...
... therapeutic agents with substantially longer duration of action than synthetic peptides. In addition to reducing dosing frequency, these technologies have the potential to substantially improve patient tolerability as compared to other evolving protein therapeutic technologies. This new platform sup ...
Teucrium polium and kidney - Journal of Renal Injury Prevention
... to examine the probable renal injury. Five other groups were injected the same drug regimen, but they were killed 28 days after discontinuation of Teucrium polium injections to find out possible renal complications or regeneration during recovery. Following 28 days of Teucrium polium receiving (phas ...
... to examine the probable renal injury. Five other groups were injected the same drug regimen, but they were killed 28 days after discontinuation of Teucrium polium injections to find out possible renal complications or regeneration during recovery. Following 28 days of Teucrium polium receiving (phas ...
Chapter Sixteen: Using Drugs Responsibly
... – Lifestyle drugs are sold to basically healthy middle-class Americans. – Lifestyle drugs are used in the place of making healthy choices such as eating a diet of vegetables and fruit and staying active. – Psychotropic drugs—useful for treating specific diseases but not intended to mask problems cau ...
... – Lifestyle drugs are sold to basically healthy middle-class Americans. – Lifestyle drugs are used in the place of making healthy choices such as eating a diet of vegetables and fruit and staying active. – Psychotropic drugs—useful for treating specific diseases but not intended to mask problems cau ...
novel paradigms for drug discovery shotgun
... SUITABILITY FOR THE PIONEER AWARD Not good for Pharma because of reuse of existing drugs (most profit in novel compounds) Not good for Pharma because of focus on third world/neglected diseases. ...
... SUITABILITY FOR THE PIONEER AWARD Not good for Pharma because of reuse of existing drugs (most profit in novel compounds) Not good for Pharma because of focus on third world/neglected diseases. ...
(1)
... One third reduction in the duration of anti-TB therapy & a two third reduction in TB relapse • This led to reduction in duration of therapy to 6 ...
... One third reduction in the duration of anti-TB therapy & a two third reduction in TB relapse • This led to reduction in duration of therapy to 6 ...
Nano-E™: Nanoemulsion Drug Delivery System
... RFAP™ Matrix Powder Formulation for Extremely Insoluble Oral Drug Candidates Nearly half of new drug candidates in development are poorly soluble compounds. Of these, many are extremely insoluble and lack any appreciable water or oil solubility, making them unformulatable using conventional approac ...
... RFAP™ Matrix Powder Formulation for Extremely Insoluble Oral Drug Candidates Nearly half of new drug candidates in development are poorly soluble compounds. Of these, many are extremely insoluble and lack any appreciable water or oil solubility, making them unformulatable using conventional approac ...
full prescribing information
... QT Prolongation: May cause an increase in QT interval. Avoid use in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. (5.2) ...
... QT Prolongation: May cause an increase in QT interval. Avoid use in patients with congenital long QT syndrome or with arrhythmias associated with a prolonged QT interval. (5.2) ...
dermatology - Bradford VTS
... occurs in the 2 hours around mid-day. Cloud cover gives little protection from UV light. 9 SCABIES Most effective treatments - lyclear dermal cream & derbac-m. Important to treat the head and neck in adults as well. Resistance about. Oral ivermectin can occasionally be used 10 EXCORIATIONS Treat ast ...
... occurs in the 2 hours around mid-day. Cloud cover gives little protection from UV light. 9 SCABIES Most effective treatments - lyclear dermal cream & derbac-m. Important to treat the head and neck in adults as well. Resistance about. Oral ivermectin can occasionally be used 10 EXCORIATIONS Treat ast ...
Investigational New Drug (IND) Submission checklist
... Need for studies depend on the nature of the drug and the phase of human investigation, including acute, sub-acute and chronic toxicity tests, tests on reproduction and fetal effects, any special toxicity tests unique to the product’s use (e.g., dermal, inhalation, etc.) and any necessary in vitro t ...
... Need for studies depend on the nature of the drug and the phase of human investigation, including acute, sub-acute and chronic toxicity tests, tests on reproduction and fetal effects, any special toxicity tests unique to the product’s use (e.g., dermal, inhalation, etc.) and any necessary in vitro t ...
DRUG NAME: Tocilizumab
... SIDE EFFECTS: The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical ...
... SIDE EFFECTS: The table includes adverse events that presented during drug treatment but may not necessarily have a causal relationship with the drug. Because clinical trials are conducted under very specific conditions, the adverse event rates observed may not reflect the rates observed in clinical ...
From prescription-only to over-the
... scheme would have been ideal for this drug and indication. Now consider how simvastatin for long-term prophylaxis of cardiovascular disease22 might have been made available under such a scheme. Its over-the-counter formulation has been restricted to 10-mg tablets, too low a dose for a full beneficia ...
... scheme would have been ideal for this drug and indication. Now consider how simvastatin for long-term prophylaxis of cardiovascular disease22 might have been made available under such a scheme. Its over-the-counter formulation has been restricted to 10-mg tablets, too low a dose for a full beneficia ...
Challenges in Implementing a Consistent SDTM
... Diverse Standards for CRFs and Raw Data Each company had its own CRF and data base standard Indication standards within the same company different ...
... Diverse Standards for CRFs and Raw Data Each company had its own CRF and data base standard Indication standards within the same company different ...
UNIVERSITY OF KENTUCKY
... couldn’t possible be useful as drugs Patients only want to use therapies (drugs) that are proven safe and effective and approved by the FDA We don’t know how herbs work. There’s very little, well documented data on mechanism of action ...
... couldn’t possible be useful as drugs Patients only want to use therapies (drugs) that are proven safe and effective and approved by the FDA We don’t know how herbs work. There’s very little, well documented data on mechanism of action ...
Pages 12-15 - eCM journal
... has been limited by the low effective concentration at the tumor site and from the systemic toxicity of these drugs. FeRx’s lead product is based on doxorubicin, a widely used chemotherapeutic agent. Many other chemotherapeutic drugs have been shown to adsorb onto the MTCs, such as mitomycin C, etop ...
... has been limited by the low effective concentration at the tumor site and from the systemic toxicity of these drugs. FeRx’s lead product is based on doxorubicin, a widely used chemotherapeutic agent. Many other chemotherapeutic drugs have been shown to adsorb onto the MTCs, such as mitomycin C, etop ...
Understanding the Japanese culture and approval process
... global market. However, the rate of growth is slower than the Western market at approximately 2% per year. The population of 127 million is rapidly ageing but generally wealthy and highly educated. All patients are covered by some form of private and/or public insurance which can cover up to 3rd deg ...
... global market. However, the rate of growth is slower than the Western market at approximately 2% per year. The population of 127 million is rapidly ageing but generally wealthy and highly educated. All patients are covered by some form of private and/or public insurance which can cover up to 3rd deg ...
19 Common pharmacology
... It is necessary to exclude such products which contain DOPA and thiramine (which is formed from casein during the process of transforming under the influence of bacteria) Aged cheese, kefir Marinated herring Smoked meat and fish Red vine, beer, yeast Beans, oranges, tangerines, lemons, grape, chocol ...
... It is necessary to exclude such products which contain DOPA and thiramine (which is formed from casein during the process of transforming under the influence of bacteria) Aged cheese, kefir Marinated herring Smoked meat and fish Red vine, beer, yeast Beans, oranges, tangerines, lemons, grape, chocol ...
Bad Pharma
.JPG?width=300)
Bad Pharma: How Drug Companies Mislead Doctors and Harm Patients is a book by British physician and academic Ben Goldacre about the pharmaceutical industry, its relationship with the medical profession, and the extent to which it controls academic research into its own products. The book was published in September 2012 in the UK by the Fourth Estate imprint of HarperCollins, and in February 2013 in the United States by Faber and Faber.Goldacre argues in the book that ""the whole edifice of medicine is broken"" because the evidence on which it is based is systematically distorted by the pharmaceutical industry. He writes that the industry finances most of the clinical trials into its own products and much of doctors' continuing education, that clinical trials are often conducted on small groups of unrepresentative subjects and negative data is routinely withheld, and that apparently independent academic papers may be planned and even ghostwritten by pharmaceutical companies or their contractors, without disclosure. Goldacre calls the situation a ""murderous disaster,"" and makes suggestions for action by patients' groups, physicians, academics and the industry itself.Responding to the book's publication, the Association of the British Pharmaceutical Industry issued a statement arguing that the examples the book offers are historical, that the concerns have been addressed, that the industry is among the most regulated in the world, and that it discloses all data in accordance with international standards.In January 2013 Goldacre joined the Cochrane Collaboration, British Medical Journal and others in setting up AllTrials, a campaign calling for the results of all past and current clinical trials to be reported. The British House of Commons Public Accounts Committee expressed concern in January 2014 that drug companies were still only publishing around 50 percent of clinical-trial results.